NCT lookup

Inclusion criteria:

* Diagnosis of rheumatoid arthritis ≥6 months duration and American College of Rheumatology (ACR) Class I-III functional status at screening and baseline visits;
* Active disease defined as:

  * At least 6 of 68 tender joints and 6 of 66 swollen joints at screening and baseline visits, and
  * hs-C-Reactive Protein (hs-CRP) \>10 g/L or Erythrocyte Sedimentation Rate (ESR) \>28 mm/hr at screening visit;
* Continuous treatment with Methotrexate for at least 12 weeks and on stable dose (minimum 10 mg/week) for at least 6 weeks prior to the screening visit;
* Participant considered as Primary TNF-α blocker nonresponder. i.e.:

  * Appropriate for previous TNF-α blocker therapy
  * Lack of adequate clinical response after at least 3 months TNF-α blocker therapy with MTX or other synthetic disease modifying anti-rheumatic drug (DMARD) co-therapy.

Exclusion criteria:

* Age \<18 years or \>75 years;
* Pregnant or breastfeeding woman or woman of childbearing potential, unwilling to utilize adequate contraception or not to become pregnant during the entire study;
* Fever (\>38°C), or chronic, persistent, or recurring infection(s);
* History of demyelinating disease;
* Current underlying hepatobiliary disease.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

• Freehold, New Jersey, United States
• New York, New York, United States
• Jackson, Tennessee, United States
• Austin, Texas, United States
• Barranquilla, Colombia
• Barranquilla, Colombia
• Bucaramanga, Colombia
• Uherské Hradiště, Czechia
• Florence, Italy
• Genova, Italy
• Durango, Mexico
• Guadalajara, Mexico
• Oviedo, Spain
• Valencia, Spain